The phase II, multicenter Destiny Lung-01 trial showed T-Dxd efficacy in two cohorts of NSCLC patients refractory to standard treatment and defined by HER2 mutations or overexpression. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.